Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 206

Results For "NSE"

2557 News Found

Japan tops CPhI ‘API Quality’ ranking for second year
News | March 13, 2022

Japan tops CPhI ‘API Quality’ ranking for second year

Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers


China approves BeiGene’s tislelizumab
Drug Approval | March 12, 2022

China approves BeiGene’s tislelizumab

Tislelizumab is now approved for seven indications in China


BioPharma’s Herceptin biosimilar Phase 3 results positive
Biotech | March 12, 2022

BioPharma’s Herceptin biosimilar Phase 3 results positive

The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile


AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases
Biotech | March 11, 2022

AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases

Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products


Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals
interviews | March 10, 2022

Glaucoma is the leading cause of irreversible blindness in India: Mr. Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals

As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma


Metropolis Healthcare announces 2nd edition of Healthcare Heroes awards
Clinical Trials | March 10, 2022

Metropolis Healthcare announces 2nd edition of Healthcare Heroes awards

As a part of its CSR initiatives, the ‘Healthcare Heroes of India’ Awards by Metropolis aims to identify and recognize those individuals and institutions in healthcare sector with a strong sense of purpose and commitment towards patient care and who have prioritized it over all other growth parameters


Gufic Biosciences collaborates with Selvax for cancer treatment
Biotech | March 10, 2022

Gufic Biosciences collaborates with Selvax for cancer treatment

Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours


Artificial retinal device mimics human optical illusions: WPI-MANA
Biotech | March 10, 2022

Artificial retinal device mimics human optical illusions: WPI-MANA

The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte


Molecular Health and researchers prove new approach to anticipate molecular causation
Biotech | March 10, 2022

Molecular Health and researchers prove new approach to anticipate molecular causation

The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts


USFDA approves Evoke Spinal Cord Stimulation System
Drug Approval | March 09, 2022

USFDA approves Evoke Spinal Cord Stimulation System

Transformative closed-loop technology senses the spinal cord's response to stimulation and instantaneously adjusts therapy to sustain durable, optimized treatment